

Câncer de Pâncreas

5-Fluorouracil + Radioterapia

5-Fluorouracil: 500 mg/m²/dia IV D1 a 3 e D29 a 31
seguido de 5-Fluorouracil semanal iniciando no D71 Ref. (1)

5-Fluorouracil + Leucovorin

5-Fluorouracil: 425 mg/m² IV D1 a 5
Leucovorin: 20 mg/m² IV D1 a 5
a cada 28 dias Ref. (2)

Gencitabina + Capecitabina

Gencitabina: 1.000 mg/m² IV D1 e 8
Capecitabina: 650 mg/m² VO BID D1 a 14
a cada 21 dias Ref. (3)

Gencitabina + Cisplatina

Gencitabina: 1.000 mg/m² IV D1, 8 e 15
Cisplatina: 50 mg/m² IV D1 e 15
a cada 28 dias Ref. (4)

GEMOX

Gencitabina: 1.000 mg/m² IV a 10 mg/m²/min D1
Oxaliplatina: 100 mg/m² IV em 2 horas D2
a cada 2 semanas Ref. (5)

Gencitabina + Irinotecano

Gencitabina: 1.000 mg/m² IV em 30 minutos D1 e 8
Irinotecano: 100 mg/m² IV em 90 minutos D1 e 8
a cada 21 dias Ref. (6)

FAM

5-Fluorouracil: 600 mg/m² IV D1, 8, 29 e 36

Adriamicina: 30 mg/m² IV D1 e 29

Mitomicina-C: 10 mg/m² IV D1

a cada 56 dias

Ref. (7)

Gencitabina + Erlotinibe

Gencitabina: 1.000 mg/m² IV semanalmente por 7 semanas, seguida por uma semana de descanso e ciclos subsequentes com Gencitabina 1.000 mg/m² IV semanalmente por 3 semanas com uma semana de descanso

Erlotinibe: 100 mg VO diariamente

Repetir o ciclo de 3 semanas a cada 28 dias

Ref. (8)

Gencitabina

Gencitabina: 1,000 mg/m² IV semanalmente por 7 semanas, seguido por uma semana de descanso

Com ciclos subsequentes de 1.000mg/m², IV semanalmente por 3 semanas com uma semana de descanso

Repetir o ciclo de 3 semanas a cada 28 dias

Ref. (9)

OU

Gencitabina: 1.000 mg/m² IV a 10 mg/m²/min D1, 8 e 15

a cada 28 dias

Ref. (10)

Capecitabina

Capecitabina: 1.250 mg/m² VO BID D1 a 14

a cada 21 dias

Ref. (11)

FOLFOX6

Oxaliplatina: 100mg/m² IV em 2 horas D1

Leucovorin: 400mg/m² IV D1

5-Fluorouracil: 400mg/m² IV pulso D1

5-Fluorouracil: 3000mg/m² IV em 46 horas.

a cada 15 dias

Ref. (12)

Gencitabina + Docetaxel + Capecitabina (GTX)

Gencitabina: 750 mg/m² IV no D4 e D11

Docetaxel: 30 mg/m² IV no D4 e D11

Capecitabina: 1000-1500 mg/m² VO duas vezes ao dia do D1 ao D14

a cada 2 semanas

Ref. (13)

FOLFIRINOX

Oxaliplatina: 85mg/m² IV em 2h D1

Irinotecano: 180mg/ m² IV em 30 a 90 minutos D1

Leucovorin: 400mg/ m² IV D1 seguido de

5-Fluorouracil 400mg/ m² em pulso D1, seguido de 5-Fluorouracil 2400 mg/m² IV contínuo em 46 horas.

a cada 2 semanas

Ref. (14)

Irinotecano

Irinotecano: 350 mg/m² IV D1 21 dias

Ref. (15)

Docetaxel

Docetaxel: 75 mg/m² IV D1 21 dias

Ref. (16)

1. Gastrointestinal Tumor Study Group. Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. *Int J Radiat Oncol Biol Phys* 1979; 5: 1643–1647.
2. DeCaprio JA, *et al.* Fluorouracil e high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. *J Clin Oncol* 1991; 9: 2128–2133.
3. Hess V, *et al.* Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. *J Clin Oncol* 2003;21:66–68.

4. Philip PA, *et al.* Phase II study of gemcitabine ecisplatin in the treatment of patients with advanced pancreatic carcinoma. *J Clin Oncol* 2001; 92:569–577.
5. Louvet C, *et al.* Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. *J Clin Oncol* 2002; 20: 1512–1518.
6. Rocha-Lima C, *et al.* Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. *J Clin Oncol* 2002;20:1182–1191.
7. Leonard RC, *et al.* Chemotherapy prolongs survival in inoperable pancreatic carcinoma. *Br J Cancer* 1994; 81: 882–885.
8. Moore MJ, *et al.* Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the NCIC-CTG. *J Clin Oncol* 2005; 23:165 (abstract 1).
9. Burris HA, *et al.* Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997;15:2403–2413.
10. BreR, *et al.* A phase I trial of semantically gemcitabine administered as a prolonged infusion in patients with pancreatic cancer or other solid tumors. *Invest New Drugs* 1997;15:331–341.
11. Cartwright TH, *et al.* Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. *J Clin Oncol* 2002; 20:160–164.
12. Ghosn M, Farhat F, Kattan J, Younes F, Moukadem W, Nasr F, Chahine G. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. *Am J Clin Oncol.* 2007 Feb;30(1):15-20.
13. Fine RL, *et al.* The GTX regimen: a biochemically synergistic combination for advanced pancreatic cancer (PC). *Proc Am Soc Clin Oncol* 2003;22:281 (abstract 1129).

- 14.** T. Conroy, F. Desseigne, *et al.* Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 4010).
- 15.** Wagener DJ, *et al.* Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. *Ann Oncol* 1995;6:129-32.
- 16.** Lenzi RL, *et al.* Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. *Cancer Invest* 2002; 20: 464-72. *Câncer Invest* 2002;20:464-72.